CBER Designing Triage System For Gene Therapy Submissions In Lieu Of ‘First In, First Out’ System

Ideally, the system will prevent some cell and gene therapy programs from slowing, CBER Director Peter Marks says.

Patient triage tent
CBER wants to triage cell and gene therapy submissions after sponsors raised concerns about timeliness. • Source: Alamy

Cell and gene therapy sponsors could see some submissions gain attention at the US Food and Drug Administration sooner that those already on file if they are deemed more important to the development program.

Center for Biologics Evaluation and Research Director Peter Marks said staff are working on a triage process for some submissions,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

test carousel-PINKSHEET

 
• By 

test carousel-test

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says - Clone

 
• By 

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Testing all options - Akash

 
• By 

This is an test article.

More from Advanced Technologies

CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged

 
• By 

Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.

test

 
• By 

test

Gene Therapies: CoGenT Pilot Could Help With Regulatory Convergence Earlier In Development TEST

 
• By 

Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.